^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Iqirvo (elafibranor)

    i
    Other names: GFT505, GFT 505, GFT-505, IPN60190
    Associations

    News

    Trials
    Company:
    Genfit, Ipsen
    Drug class:
    PPAR α agonist, PPAR δ agonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Compound 3d Attenuates Metabolic Dysfunction-Associated Steatohepatitis via Peroxisome Proliferator-Activated Receptor Pathway Activation and Inhibition of Inflammatory and Apoptotic Signaling. (PubMed, Metabolites)
    This study aimed to evaluate the therapeutic potential of compound 3d, a novel elafibranor derivative, focusing on its dual mechanisms of PPAR pathway activation and p38 MAPK signaling inhibition... Compound 3d alleviates MASH via PPAR-mediated lipid metabolism enhancement and p38 MAPK-driven inflammation/apoptosis suppression, with additional gut microbiota modulation. These findings highlight 3d as a multi-target therapeutic candidate for MASH.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP8 (Caspase 8) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ACOX1 (Acyl-CoA Oxidase 1)
    |
    Iqirvo (elafibranor)
    7ms
    ELSPIRE: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (clinicaltrials.gov)
    P3, N=69, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Iqirvo (elafibranor)
    9ms
    Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. (PubMed, World J Biol Chem)
    Future research should focus on elucidating EFN's molecular mechanisms and advancing its clinical application to establish its therapeutic potential in human populations. EFN represents a novel, comprehensive strategy for ALD management, targeting both liver and gut pathologies.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    Iqirvo (elafibranor)
    10ms
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Recruiting, Ipsen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iqirvo (elafibranor)
    10ms
    ELFINITY: A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (clinicaltrials.gov)
    P=N/A, N=424, Recruiting, Ipsen | Trial completion date: Jul 2029 --> Jul 2032 | Trial primary completion date: Jul 2029 --> Jul 2032
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Iqirvo (elafibranor)
    12ms
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Not yet recruiting, Ipsen
    New P3 trial
    |
    Iqirvo (elafibranor)
    1year
    Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. (PubMed, World J Gastroenterol)
    Additionally, alcohol disrupts the gut-liver axis at several interconnected levels, contributing to a proinflammatory environment in the liver. EFN helps alleviate intestinal hyperpermeability by restoring tight junction protein expression and autophagy, inhibiting apoptosis and inflammatory responses, and enhancing intestinal barrier function through PPARδ activation.
    Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    Iqirvo (elafibranor)
    1year
    ELMWOOD: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Ipsen | Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Dec 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Iqirvo (elafibranor)
    1year
    ELFIDENCE: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=276, Recruiting, Ipsen | Trial completion date: May 2030 --> May 2029
    Trial completion date
    |
    Iqirvo (elafibranor)
    1year
    Dual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease? (PubMed, World J Gastroenterol)
    In this letter, we review the article "Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease"...Furthermore, we summarize the clinical management of all stages of ALD and present new insights into its pathogenesis and potential therapeutic targets. Additionally, we discuss the mechanisms of action of PPARα and δ agonists, the significance of their antifibrotic effects on ALD and future research directions.
    Review • Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    Iqirvo (elafibranor)
    1year
    ELFIDENCE: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=276, Recruiting, Ipsen | Trial completion date: May 2029 --> May 2030
    Trial completion date
    |
    Iqirvo (elafibranor)
    1year
    ELFINITY: A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (clinicaltrials.gov)
    P=N/A, N=424, Recruiting, Ipsen | Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Oct 2024
    Enrollment open • Trial initiation date
    |
    Iqirvo (elafibranor)